From Inuit to implementation: Omega-3 fatty acids come of age

James H. O'Keefe, William Harris

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

During the past 25 years, the cardiovascular effects of marine omega-3 (ω-3) fatty acids have been the subject of increasing investigation. In the late 1970s, epidemiological studies revealed that Greenland Inuits had substantially reduced rates of acute myocardial infarction compared with Western control subjects. These observations generated more than 4500 studies to explore this and other effects of ω-3 fatty acids on human metabolism and health. From epidemiology to cell culture and animal studies to randomized controlled trials, the cardioprotective effects of ω-3 fatty acids are becoming recognized. These fatty acids, when incorporated into the diet at levels of about 1 g/d, seem to be able to stabilize myocardial membranes electrically, resulting in reduced susceptibility to ventricular dysrhythmias, thereby reducing the risk of sudden death. The recent GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico)- Prevention study of 11,324 patients showed a 45% decrease in risk of sudden cardiac death and a 20% reduction in all-cause mortality in the group taking 850 mg/d of ω-3 fatty acids. These fatty acids have potent anti-inflammatory effects and may also be antiatherogenic. Higher doses of ω-3 fatty acids can lower elevated serum triglyceride levels; 3 to 5 g/d can reduce triglyceride levels by 30% to 50%, minimizing the risk of both coronary heart disease and acute pancreatitis. This review summarizes the emerging evidence of the use of ω-3 fatty acids in the prevention of coronary heart disease.

Original languageEnglish (US)
Pages (from-to)607-614
Number of pages8
JournalMayo Clinic Proceedings
Volume75
Issue number6
StatePublished - 2000
Externally publishedYes

Fingerprint

Omega-3 Fatty Acids
Fatty Acids
Coronary Disease
Triglycerides
Greenland
Sudden Cardiac Death
Sudden Death
Pancreatitis
Epidemiologic Studies
Epidemiology
Anti-Inflammatory Agents
Randomized Controlled Trials
Cell Culture Techniques
Myocardial Infarction
Diet
Membranes
Mortality
Health
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

O'Keefe, J. H., & Harris, W. (2000). From Inuit to implementation: Omega-3 fatty acids come of age. Mayo Clinic Proceedings, 75(6), 607-614.

From Inuit to implementation : Omega-3 fatty acids come of age. / O'Keefe, James H.; Harris, William.

In: Mayo Clinic Proceedings, Vol. 75, No. 6, 2000, p. 607-614.

Research output: Contribution to journalArticle

O'Keefe, JH & Harris, W 2000, 'From Inuit to implementation: Omega-3 fatty acids come of age', Mayo Clinic Proceedings, vol. 75, no. 6, pp. 607-614.
O'Keefe, James H. ; Harris, William. / From Inuit to implementation : Omega-3 fatty acids come of age. In: Mayo Clinic Proceedings. 2000 ; Vol. 75, No. 6. pp. 607-614.
@article{441742e9308a41749966d54d5be87899,
title = "From Inuit to implementation: Omega-3 fatty acids come of age",
abstract = "During the past 25 years, the cardiovascular effects of marine omega-3 (ω-3) fatty acids have been the subject of increasing investigation. In the late 1970s, epidemiological studies revealed that Greenland Inuits had substantially reduced rates of acute myocardial infarction compared with Western control subjects. These observations generated more than 4500 studies to explore this and other effects of ω-3 fatty acids on human metabolism and health. From epidemiology to cell culture and animal studies to randomized controlled trials, the cardioprotective effects of ω-3 fatty acids are becoming recognized. These fatty acids, when incorporated into the diet at levels of about 1 g/d, seem to be able to stabilize myocardial membranes electrically, resulting in reduced susceptibility to ventricular dysrhythmias, thereby reducing the risk of sudden death. The recent GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico)- Prevention study of 11,324 patients showed a 45{\%} decrease in risk of sudden cardiac death and a 20{\%} reduction in all-cause mortality in the group taking 850 mg/d of ω-3 fatty acids. These fatty acids have potent anti-inflammatory effects and may also be antiatherogenic. Higher doses of ω-3 fatty acids can lower elevated serum triglyceride levels; 3 to 5 g/d can reduce triglyceride levels by 30{\%} to 50{\%}, minimizing the risk of both coronary heart disease and acute pancreatitis. This review summarizes the emerging evidence of the use of ω-3 fatty acids in the prevention of coronary heart disease.",
author = "O'Keefe, {James H.} and William Harris",
year = "2000",
language = "English (US)",
volume = "75",
pages = "607--614",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - From Inuit to implementation

T2 - Omega-3 fatty acids come of age

AU - O'Keefe, James H.

AU - Harris, William

PY - 2000

Y1 - 2000

N2 - During the past 25 years, the cardiovascular effects of marine omega-3 (ω-3) fatty acids have been the subject of increasing investigation. In the late 1970s, epidemiological studies revealed that Greenland Inuits had substantially reduced rates of acute myocardial infarction compared with Western control subjects. These observations generated more than 4500 studies to explore this and other effects of ω-3 fatty acids on human metabolism and health. From epidemiology to cell culture and animal studies to randomized controlled trials, the cardioprotective effects of ω-3 fatty acids are becoming recognized. These fatty acids, when incorporated into the diet at levels of about 1 g/d, seem to be able to stabilize myocardial membranes electrically, resulting in reduced susceptibility to ventricular dysrhythmias, thereby reducing the risk of sudden death. The recent GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico)- Prevention study of 11,324 patients showed a 45% decrease in risk of sudden cardiac death and a 20% reduction in all-cause mortality in the group taking 850 mg/d of ω-3 fatty acids. These fatty acids have potent anti-inflammatory effects and may also be antiatherogenic. Higher doses of ω-3 fatty acids can lower elevated serum triglyceride levels; 3 to 5 g/d can reduce triglyceride levels by 30% to 50%, minimizing the risk of both coronary heart disease and acute pancreatitis. This review summarizes the emerging evidence of the use of ω-3 fatty acids in the prevention of coronary heart disease.

AB - During the past 25 years, the cardiovascular effects of marine omega-3 (ω-3) fatty acids have been the subject of increasing investigation. In the late 1970s, epidemiological studies revealed that Greenland Inuits had substantially reduced rates of acute myocardial infarction compared with Western control subjects. These observations generated more than 4500 studies to explore this and other effects of ω-3 fatty acids on human metabolism and health. From epidemiology to cell culture and animal studies to randomized controlled trials, the cardioprotective effects of ω-3 fatty acids are becoming recognized. These fatty acids, when incorporated into the diet at levels of about 1 g/d, seem to be able to stabilize myocardial membranes electrically, resulting in reduced susceptibility to ventricular dysrhythmias, thereby reducing the risk of sudden death. The recent GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico)- Prevention study of 11,324 patients showed a 45% decrease in risk of sudden cardiac death and a 20% reduction in all-cause mortality in the group taking 850 mg/d of ω-3 fatty acids. These fatty acids have potent anti-inflammatory effects and may also be antiatherogenic. Higher doses of ω-3 fatty acids can lower elevated serum triglyceride levels; 3 to 5 g/d can reduce triglyceride levels by 30% to 50%, minimizing the risk of both coronary heart disease and acute pancreatitis. This review summarizes the emerging evidence of the use of ω-3 fatty acids in the prevention of coronary heart disease.

UR - http://www.scopus.com/inward/record.url?scp=0034045541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034045541&partnerID=8YFLogxK

M3 - Article

C2 - 10852422

AN - SCOPUS:0034045541

VL - 75

SP - 607

EP - 614

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -